{"filings":[{"id":1949404,"accession_number":"0001104659-26-088393","cik":1379006,"company_name":"NANOVIRICIDES, INC.","ticker":"NNVC","form_type":"8-K","filed_at":"2026-07-30T10:02:18+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"NanoViricides raises ~$3.8M in registered direct offering of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$3.8M from sale of 2,516,339 shares (or pre-funded warrants) and warrants to purchase 2,516,339 shares at $1.75.","Offering closed on July 27, 2026; net proceeds for working capital, R&D, clinical trials, and strategic purposes.","CEO and principal stockholder TheraCour Pharma entered 30-day lock-up agreements restricting share sales.","D. Boral Capital acted as exclusive placement agent with 7.0% cash fee and up to $50,000 expense reimbursement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":39614008.95428572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1720439,"accession_number":"0001104659-26-084668","cik":1379006,"company_name":"NANOVIRICIDES, INC.","ticker":"NNVC","form_type":"8-K","filed_at":"2026-07-17T20:45:18+00:00","items":["1.01","9.01"],"status":"ready","headline":"NanoViricides enters into at-the-market sales agreement with D. Boral Capital for common stock offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company entered into an At Market Issuance Sales Agreement with D. Boral Capital LLC for at-the-market sales of common stock.","Sales agent commission set at 2.0% of gross proceeds from each sale.","Shares may be sold on NYSE American or other trading markets; no minimum amount specified.","Agreement terminates upon sale of all shares or termination by either party."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":39614008.95428572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":563120,"accession_number":"0001104659-26-064754","cik":1379006,"company_name":"NANOVIRICIDES, INC.","ticker":"NNVC","form_type":"8-K","filed_at":"2026-05-21T10:01:46+00:00","items":["7.01"],"status":"ready","headline":"NanoViricides says NV-387 and NV-387-remdesivir expected to be effective against Ebola Bundibugyo strain in DRC","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["NV-387 is broad-spectrum antiviral entering Phase II for Mpox in DRC.","NV-387-remdesivir is an oral formulation shown in animal models; PLOS ONE paper published.","Encapsulation protects remdesivir from metabolism, improving efficacy per company.","Company has a clinical site in DRC for Mpox; public health responders to decide on Ebola.","Remdesivir was tested in prior Ebola trials but efficacy not established; antibodies approved only for Zaire strain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":39614008.95428572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":555320,"accession_number":"0001104659-26-064544","cik":1379006,"company_name":"NANOVIRICIDES, INC.","ticker":"NNVC","form_type":"8-K","filed_at":"2026-05-20T20:30:33+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"NanoViricides raises $2M in registered direct offering of shares and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 1,333,334 shares (or pre-funded warrants) plus 1,333,334 warrants at $1.75, priced at $1.50 per share.","Gross proceeds $2,000,001; closed May 18, 2026; D. Boral Capital as placement agent.","Single institutional investor purchased entire offering; CEO agreed to 30-day lock-up.","Net proceeds to fund working capital, R&D, and clinical trial expenses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":39614008.95428572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119657,"accession_number":"0001104659-25-116457","cik":1379006,"company_name":"NANOVIRICIDES, INC.","ticker":"NNVC","form_type":"8-K","filed_at":"2025-11-26T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"NanoViricides annual meeting approves director re-election, executive compensation, auditor ratification","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Anil Diwan re-elected as Class I Director with 9,757,652 votes in favor, 173,096 against.","Advisory vote on executive compensation passed: 9,500,223 for, 420,374 against.","Ratification of EisnerAmper as auditor for fiscal year ending June 30, 2026 passed: 14,594,257 for, 194,416 against.","Meeting held November 22, 2025; quorum of ~61% of outstanding voting capital stock present."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":39614008.95428572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119656,"accession_number":"0001104659-25-112644","cik":1379006,"company_name":"NANOVIRICIDES, INC.","ticker":"NNVC","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"NanoViricides raises $6M in registered direct offering and private placement with warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offered 3,571,429 shares (or pre-funded equivalents) at $1.68/share for gross proceeds of ~$6M.","Concurrent private placement of Series A warrants (3.57M shares, $1.75 exercise, 2yr) and Series B warrants (3.57M shares, $2.00 exercise, 5.5yr).","Offering closed Nov 12, 2025; net proceeds for working capital and general corporate purposes.","Directors and executive officers entered into 90-day lock-up agreements following closing.","A.G.P./Alliance Global Partners acted as sole placement agent with 7% cash fee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":39614008.95428572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119655,"accession_number":"0001104659-25-095676","cik":1379006,"company_name":"NANOVIRICIDES, INC.","ticker":"NNVC","form_type":"8-K","filed_at":"2025-10-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"NanoViricides extends CEO/CFO contracts; raises CEO line of credit to $3M through 2027","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["President/CEO Diwan term extended to June 30, 2026; base salary $400,000/yr; granted 10,204 Series A preferred shares vesting quarterly.","CFO Vyas term extended to June 30, 2026; compensation $10,800/month; health insurance reimbursement up to $2,500/month.","CEO Diwan's line of credit increased from $2M to $3M; maturity extended to March 31, 2027; 12% interest; secured by company property."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":39614008.95428572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189067,"accession_number":"0001104659-24-128066","cik":1379006,"company_name":"NANOVIRICIDES, INC.","ticker":"NNVC","form_type":"8-K","filed_at":"2024-12-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"NanoViricides shareholders re-elect three directors and ratify auditor at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Theodore Rokita re-elected with 2,060,147 votes for, 166,389 against.","Makarand Jawadekar re-elected with 1,951,381 votes for, 272,416 against.","Brian Zucker re-elected with 2,088,483 votes for, 139,413 against.","EisnerAmper LLP ratified as auditor for FY ending June 30, 2025 with 5,757,913 votes for.","Meeting quorum of 47.1% with 6,096,059 common and 883,177 Series A Preferred shares present."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":39614008.95428572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205551,"accession_number":"0001104659-24-087828","cik":1379006,"company_name":"NANOVIRICIDES, INC.","ticker":"NNVC","form_type":"8-K","filed_at":"2024-08-09T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"NanoViricides extends President Diwan ($400k, 10k Series A shares) and CFO Vyas through June 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["President Anil Diwan's employment extended to June 30, 2025 at $400,000 base salary.","Diwan receives 10,204 Series A Preferred shares, vesting quarterly over the one-year term.","CFO Meeta Vyas extended on same general terms; new health insurance reimbursement up to $2,500/month.","Diwan eligible for six months' severance if terminated without cause, plus continued benefits."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":39614008.95428572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222486,"accession_number":"0001104659-24-044367","cik":1379006,"company_name":"NANOVIRICIDES, INC.","ticker":"NNVC","form_type":"8-K","filed_at":"2024-04-05T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"NanoViricides names EF Hutton as sole sales agent for $50M ATM, removes B. Riley","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["EF Hutton LLC becomes sole agent under existing $50M at-the-market offering; B. Riley Securities removed.","Company may sell shares at its discretion; no obligation to issue any shares.","Commission of 3% of gross proceeds; reimburses Agent $50k initial plus $2.5k/quarter expenses.","Sales made under effective shelf registration S-3 (No. 333-271706) and related prospectus supplements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":39614008.95428572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242006,"accession_number":"0001104659-24-024973","cik":1379006,"company_name":"NANOVIRICIDES, INC.","ticker":"NNVC","form_type":"8-K","filed_at":"2024-02-16T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"NanoViricides defers TheraCour milestone payments until revenue; CEO extends Line of Credit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment to TheraCour license defers future cash milestone payments (Milestones 4-7) until company achieves a Revenue Event; capped at 50% of Recognized Revenue.","Milestones 1,2,3 already paid: 100k Series A Preferred shares, 50k Series A Preferred shares, and $1.5M via 331,859 shares in lieu of cash.","CEO Dr. Anil Diwan extended $2M line of credit maturity from Dec 31, 2024 to Dec 31, 2025; no draws to date.","TheraCour agreed to suspend two-month advance payment requirement until company raises sufficient capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":39614008.95428572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242005,"accession_number":"0001104659-24-005254","cik":1379006,"company_name":"NANOVIRICIDES, INC.","ticker":"NNVC","form_type":"8-K","filed_at":"2024-01-19T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"NanoViricides shareholders re-elect Anil Diwan as director, approve executive compensation and preferred stock grant","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["At the January 13, 2024 annual meeting, shareholders re-elected Anil Diwan as Class I director with 5,590,467 votes for, 308,092 against, 488,175 abstentions, and 3,056,966 broker non-votes.","An advisory vote on named executive officer compensation passed with 5,572,378 votes for and 788,423 against, plus 3,056,966 broker non-votes.","Approval of a grant of 10,204 Series A Convertible Preferred Shares to Anil Diwan in connection with his employment extension passed with 5,508,079 votes for, 844,079 against.","Ratification of EisnerAmper LLP as independent registered public accounting firm for fiscal year ending June 30, 2024 passed with 9,165,259 votes for, 152,847 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":39614008.95428572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259407,"accession_number":"0001104659-23-114862","cik":1379006,"company_name":"NANOVIRICIDES, INC.","ticker":"NNVC","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"NanoViricides receives auditor consent for registration statement; no financial impact","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["EisnerAmper LLP consented to incorporation of its audit report from FY2023 10-K into S-3 registration statement.","No new financial results or changes to prior disclosures were made.","Registration statement (File No. 333-271706) was originally filed on May 5, 2023.","This is a customary procedural step for shelf registration maintenance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":39614008.95428572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276681,"accession_number":"0001104659-23-097802","cik":1379006,"company_name":"NANOVIRICIDES, INC.","ticker":"NNVC","form_type":"8-K","filed_at":"2023-09-01T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"NanoViricides issues $1.5M convertible note to TheraCour in lieu of milestone payment","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $1.5M convertible promissory note to TheraCour (related party) in lieu of $1.5M cash milestone payment under Licensing Agreement.","Note bears 12% annual interest, matures January 19, 2025; convertible into Series A Convertible Preferred Stock.","Dr. Anil Diwan (President/Chairman) owns ~90% of TheraCour; recused from board vote on agreement.","Note replaces milestone payment obligation for Initiation of Phase 1 Clinical Trials or Equivalent milestone.","Company retains customary representations and warranties; note is unregistered security."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":39614008.95428572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294465,"accession_number":"0001104659-23-064652","cik":1379006,"company_name":"NANOVIRICIDES, INC.","ticker":"NNVC","form_type":"8-K","filed_at":"2023-05-25T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"NanoViricides to redomicile from Nevada to Delaware effective May 30, 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board and shareholders approved conversion to a Delaware corporation.","Effective May 30, 2023; each outstanding share converts 1:1 to new Delaware shares.","No change in business, management, or stock ticker (NNVC).","Par value changes from $0.001 to $0.00001 per share.","Filing of Nevada Articles of Conversion, Delaware Certificate of Conversion and Certificate of Incorporation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":39614008.95428572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315065,"accession_number":"0001104659-23-040296","cik":1379006,"company_name":"NANOVIRICIDES, INC.","ticker":"NNVC","form_type":"8-K","filed_at":"2023-03-31T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"NanoViricides licenses COVID-19 drug candidates NV-CoV-2 and NV-CoV-2-R to Karveer for India","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusive license for development and commercialization in India; Karveer to sponsor Phase I and II clinical trials.","NanoViricides reimburses all direct/indirect trial costs plus a 30% fee; Karveer pays 70% of invoiced commercial sales to NanoViricides.","No minimum royalties or license maintenance fees; term continues as long as Karveer uses NanoViricides' proprietary technologies.","NanoViricides retains full rights to clinical data for use outside India."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":39614008.95428572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315064,"accession_number":"0001104659-23-019813","cik":1379006,"company_name":"NANOVIRICIDES, INC.","ticker":"NNVC","form_type":"8-K","filed_at":"2023-02-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"NanoViricides shareholders approve redomicile from Nevada to Delaware","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["On Feb 7, 2023, shareholders voted to reincorporate in Delaware from Nevada.","Votes: 8,115,210 for, 942,379 against; 56% of outstanding voting capital present.","Redomicile proposal was detailed in the Nov 15, 2022 proxy statement.","Series A Convertible Preferred and common stock both entitled to vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":39614008.95428572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":333404,"accession_number":"0001104659-22-129595","cik":1379006,"company_name":"NANOVIRICIDES, INC.","ticker":"NNVC","form_type":"8-K","filed_at":"2022-12-22T23:59:59+00:00","items":["5.07","8.01"],"status":"ready","headline":"NanoViricides annual meeting adjourned on redomicile proposal; directors re-elected, Diwan grant approved","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Directors Rokita (5.99M for), Jawadekar (5.95M for), Zucker (6.05M for) re-elected.","Approved 10,204 Series A Preferred Shares grant to President Anil Diwan (5.72M for, 1.01M against).","Ratified EisnerAmper as auditor for FY2023 (9.26M for, 88k against).","Redomicile to Delaware proposal did not pass; meeting adjourned to Feb 7, 2023 for further voting.","Quorum of 57% of voting shares was present at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":39614008.95428572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":333403,"accession_number":"0001104659-22-107752","cik":1379006,"company_name":"NANOVIRICIDES, INC.","ticker":"NNVC","form_type":"8-K","filed_at":"2022-10-11T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"NanoViricides extends President Diwan's employment to June 2023 at $400K salary, 10,204 Series A preferred shares","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Employment extended through June 30, 2023; annual base salary of $400,000.","Grant of 10,204 Series A Convertible Preferred shares, vesting quarterly over one year.","Series A Preferred has 9 votes per share and converts into 3.5 common shares only upon change of control; non-transferable.","Company to maintain $2M term life insurance policy on Diwan, with $1M assigned to the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":39614008.95428572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":405382,"accession_number":"0001104659-21-143985","cik":1379006,"company_name":"NANOVIRICIDES, INC.","ticker":"NNVC","form_type":"8-K","filed_at":"2021-11-26T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"NanoViricides shareholders re-elect Anil Diwan, approve preferred stock grant and advisory vote frequency","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Anil Diwan re-elected as Class I director with 5,242,989 votes for, 137,944 withheld.","Shareholders approved a three-year interval for advisory vote on executive compensation (4,925,150 votes for).","Approved grant of 10,204 Series A Preferred Shares to Anil Diwan (5,028,342 for, 343,312 against, 34,352 abstain).","Ratified EisnerAmper as independent auditor for fiscal year ending June 30, 2022 (8,638,812 for, 372,551 against).","60.7% quorum achieved at the November 20, 2021 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.15,"market_cap_usd":39614008.95428572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":424434,"accession_number":"0001104659-21-117728","cik":1379006,"company_name":"NANOVIRICIDES, INC.","ticker":"NNVC","form_type":"8-K","filed_at":"2021-09-21T23:59:59+00:00","items":["7.01","8.01"],"status":"ready","headline":"NanoViricides reports NV-CoV-2-R shows nearly 2x intact remdesivir in plasma vs standard in rat study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Almost double intact remdesivir in plasma on day 1 of dosing with NV-CoV-2-R vs standard remdesivir.","After fifth dose (day 7), circulating remdesivir 75% greater in NV-CoV-2-R group.","NV-CoV-2-R combines nanoviricides platform attack on virus outside cells with remdesivir inside cells.","Company expects improved pan-coronavirus activity retaining effectiveness against emerging variants.","Draft data inadvertently published; final press release expected by September 28, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":39614008.95428572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":424433,"accession_number":"0001104659-21-115943","cik":1379006,"company_name":"NANOVIRICIDES, INC.","ticker":"NNVC","form_type":"8-K","filed_at":"2021-09-15T23:59:59+00:00","items":["1.01","5.02"],"status":"ready","headline":"NanoViricides licenses coronavirus drug field from TheraCour; no upfront cash","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusive worldwide license for coronavirus antiviral drugs; no upfront cash payment to TheraCour.","Milestone payments include up to 750,000 Series A preferred shares and up to $11M in cash tied to clinical development.","Royalty of 15% on net sales of licensed products; TheraCour retains manufacturing rights.","President Anil Diwan's employment extended to June 30, 2022 with $400K base salary and 10,204 Series A shares vesting quarterly."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":39614008.95428572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}